Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Daniel (cancer) Le (cancer)
Phone: 346.238.5655
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, r ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator:
Phone:
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >
Status: Open Not Enrolling
Investigator: Eric Bernicker
Study Coordinator:
Phone:
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some o ... Read more >
Status: Enrolling
Investigator: Varun Rachakonda
Study Coordinator:
Phone:
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal Radiation-Spheres (SIR-spheres ... Read more >